BCAB

BioAtla (BCAB)

About BioAtla (BCAB)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Details

Daily high

$3.47

Daily low

$3.14

Price at open

$3.36

52 Week High

$71.50

52 Week Low

$3.12

Market cap

5.5M

Dividend yield

0.00%

Volume

54,017

Avg. volume

49,738

P/E ratio

-.08

BioAtla News